Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 16.3105 USD -0.12%
Market Cap: 238.9m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Anika Therapeutics Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anika Therapeutics Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Anika Therapeutics Inc
NASDAQ:ANIK
Gross Profit
$102.9m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
2%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Anika Therapeutics Inc
Glance View

Market Cap
239.7m USD
Industry
Biotechnology

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

ANIK Intrinsic Value
12.0834 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Anika Therapeutics Inc's Gross Profit?
Gross Profit
102.9m USD

Based on the financial report for Sep 30, 2024, Anika Therapeutics Inc's Gross Profit amounts to 102.9m USD.

What is Anika Therapeutics Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
2%

Over the last year, the Gross Profit growth was 2%. The average annual Gross Profit growth rates for Anika Therapeutics Inc have been 8% over the past three years , 4% over the past five years , and 2% over the past ten years .

Back to Top